Voriconazole, a novel wide‐spectrum triazole: oral pharmacokinetics and safety

Abstract

The oral dosing regimen selected for subsequent Phase II/III clinical trials on the basis of these results was 200 mg twice daily, equivalent to 3 mg kg-1 twice daily.